{"contentid": 488659, "importid": NaN, "name": "Hummingbird Bioscience raises $125 million financing", "introduction": "Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the close of its $125 million Series C financing round.", "content": "<p>Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the close of its $125 million Series C financing round.</p>\n<p>The financing was led by Novo Holdings, with significant participation from new investors including Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management. Existing investors including SK Inc, Heritas Capital, and Mirae Asset Venture Capital also joined the round.&nbsp;&nbsp;</p>\n<p>&ldquo;We are delighted to have the support and confidence of leading global healthcare investors to advance the development of our unique pipeline of precision therapies against important, yet hard-to-drug targets. We have made tremendous progress since closing our Series B in 2019 and this financing reflects strong support for our platform, people, and development strategy,&rdquo; said Piers Ingram, chief executive and co-founder of Hummingbird Bioscience. &ldquo;With our world-class team of researchers and proprietary technologies, Hummingbird is at the cutting-edge of scientific discovery. These new funds give us further resources to invest in our early-stage pipeline, as well as supporting the clinical development of our two lead programs that we believe can deliver very meaningful benefit for patients,&rdquo; he added.&nbsp;</p>\n<h2><strong>Will advance lead assets &ndash; tumor candidates HMBD-001 and HMBD-002</strong></h2>\n<p>Proceeds from the financing will be used to advance the clinical development of Hummingbird&rsquo;s lead assets including, HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumors. The funds will also be used to expand the capabilities of Hummingbird&rsquo;s proprietary Rational Antibody Discovery platform and progress the development of its next-generation pipeline of precision therapeutics including HMBD-009, a BCMA-TACI dual-specific T cell engager.&nbsp;&nbsp;&nbsp;</p>\n<p>&ldquo;We are delighted to lead this financing in Hummingbird and pleased to have attracted a syndicate of sophisticated investors to enable the acceleration of the company&rsquo;s clinical development activities. We believe that Hummingbird&rsquo;s novel data-driven, systems biology approach brings new precision to the field of antibody drug discovery and development, and we are proud to support the team in realizing their vision,&rdquo; said Kenneth Harrison, Partner, Novo Ventures.&nbsp;</p>\n<p>This is one of the first investments in a privately-held Asian biotech company by Novo Holdings, which recently established an Asian life sciences investment platform in Singapore, Novo Holdings Equity Asia Pte. Kenneth Harrison, partner, Novo Ventures, will join Hummingbird&rsquo;s board of directors.</p>", "date": "2021-05-18 14:06:00", "meta_title": "Hummingbird Bioscience raises $125 million financing", "meta_keywords": "Hummingbird Bioscience, Financing, Series C, Novo Holdings, HMBD-001. HMBD2, Tumors", "meta_description": "Hummingbird Bioscience raises $125 million financing", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-18 14:05:20", "updated": "2021-05-18 14:12:35", "access": NaN, "url": "https://www.thepharmaletter.com/article/hummingbird-bioscience-raises-125-million-financing", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "hummingbird_bioscience_large.jpg", "image2id": "hummingbird_bioscience_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Venture capital", "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Asia Pacific, Business Financing, Focus On, One to Watch Companies, Research", "geography_tag": "Denmark, Singapore", "company_tag": "Hummingbird Bioscience, Novo Holdings", "drug_tag": "HMBD-001, HMBD-002", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-18 14:06:00"}